Gen Wealth Partners Inc Has $645,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Gen Wealth Partners Inc lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,499 shares of the company’s stock after acquiring an additional 246 shares during the quarter. Gen Wealth Partners Inc’s holdings in Novo Nordisk A/S were worth $645,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. M. Kulyk & Associates LLC raised its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock valued at $274,000 after purchasing an additional 119 shares during the period. Center for Financial Planning Inc. raised its holdings in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares during the period. Tradewinds Capital Management LLC lifted its position in Novo Nordisk A/S by 2.6% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock worth $429,000 after acquiring an additional 124 shares during the last quarter. Exencial Wealth Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock worth $1,987,000 after acquiring an additional 124 shares during the period. Finally, Indie Asset Partners LLC grew its position in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after purchasing an additional 126 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $65.75 on Friday. The firm’s 50 day simple moving average is $69.21 and its 200 day simple moving average is $86.23. The firm has a market capitalization of $295.06 billion, a price-to-earnings ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $79.17 billion. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent research reports. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. BMO Capital Markets restated a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Two analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.